Trial Profile
Empagliflozin in Early Diabetic Kidney Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 24 Feb 2020 Planned End Date changed from 4 Aug 2024 to 21 Feb 2020.
- 24 Feb 2020 Planned primary completion date changed from 4 Aug 2024 to 21 Feb 2020.
- 24 Feb 2020 Planned initiation date changed from 27 Feb 2020 to 27 May 2017.